Uniongen Starts the Recombinant Bioproduct New Drug Plant Project in TEDA
On October 26, the groundbreaking ceremony for the Uniongen Recombinant Bioproduct New Drug Plant Project was held in TEDA. The project has a total investment of 700 million yuan and covers an area of 28,000 square meters. It will be constructed in two phases and will include the production line for long-acting growth hormone drugs. The first phase, with an investment of 360 million yuan, is expected to have an annual output value of 5 billion yuan after reaching full production. This project will support the development of TEDA's macromolecular drug industry and the accumulation of regional technical talents.
Uniongen Bioengineering (Suzhou) Co., Ltd. is a comprehensive enterprise focused on the research, development, and production of innovative biopharmaceuticals. The company possesses advanced genetic engineering drug production and testing equipment and has established a top-tier research and development technical team. Relying on the technology platform of human serum albumin fusion protein, the company has independently developed multiple long-acting therapeutic biopharmaceuticals and has conducted comprehensive research based on this as its major business. Currently, the company's products under development are all biopharmaceutical Class I new drugs independently developed by the company, and some of these projects have already progressed to Phase II clinical trials.
First, please LoginComment After ~